Effect of Antibacterial Prophylaxis on Febrile Neutropenic Episodes and Bacterial Bloodstream Infections in Dutch Pediatric Patients with Acute Myeloid Leukemia: A Two-Center Retrospective Study
- PMID: 35804942
- PMCID: PMC9264841
- DOI: 10.3390/cancers14133172
Effect of Antibacterial Prophylaxis on Febrile Neutropenic Episodes and Bacterial Bloodstream Infections in Dutch Pediatric Patients with Acute Myeloid Leukemia: A Two-Center Retrospective Study
Abstract
Bloodstream infections (BSIs), especially those caused by Gram-negative rods (GNR) and viridans group streptococci (VGS), are common and potentially life-threatening complications of pediatric acute myeloid leukemia (AML) treatment. Limited literature is available on prophylactic regimens. We retrospectively evaluated the effect of different antibacterial prophylaxis regimens on the incidence of febrile neutropenic (FN) episodes and bacterial BSIs. Medical records of children (0−18 years) diagnosed with de novo AML and treated at two Dutch centers from May 1998 to March 2021 were studied. Data were analyzed per chemotherapy course and consecutive neutropenic period. A total of 82 patients had 316 evaluable courses: 92 were given with single-agent ciprofloxacin, 138 with penicillin plus ciprofloxacin, and 51 with teicoplanin plus ciprofloxacin. The remaining 35 courses with various other prophylaxis regimens were not statistically compared. During courses with teicoplanin plus ciprofloxacin, significantly fewer FN episodes (43 vs. 90% and 75%; p < 0.0001) and bacterial BSIs (4 vs. 63% and 33%; p < 0.0001) occurred than with single-agent ciprofloxacin and penicillin plus ciprofloxacin, respectively. GNR and VGS BSIs did not occur with teicoplanin plus ciprofloxacin and no bacterial BSI-related pediatric intensive care unit (PICU) admissions were required, whereas, with single-agent ciprofloxacin and penicillin plus ciprofloxacin, GNR BSIs occurred in 8 and 1% (p = 0.004), VGS BSIs in 24 and 14% (p = 0.0005), and BSI-related PICU admissions were required in 8 and 2% of the courses (p = 0.029), respectively. Teicoplanin plus ciprofloxacin as antibacterial prophylaxis is associated with a lower incidence of FN episodes and bacterial BSIs. This may be a good prophylactic regimen for pediatric AML patients during treatment.
Keywords: Gram-negative rods; antibacterial prophylaxis; bloodstream infections; ciprofloxacin; febrile neutropenia; pediatric acute myeloid leukemia; teicoplanin; viridans group streptococci.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia.Ann Hematol. 2017 Jan;96(1):99-106. doi: 10.1007/s00277-016-2833-5. Epub 2016 Oct 4. Ann Hematol. 2017. PMID: 27699447 Free PMC article.
-
Incidence of Bloodstream Infections in Pediatric Patients with Cancer during Febrile Neutropenia: A Retrospective Study.JMA J. 2025 Apr 28;8(2):560-567. doi: 10.31662/jmaj.2024-0369. Epub 2025 Mar 28. JMA J. 2025. PMID: 40416004 Free PMC article.
-
Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.Cancer. 2014 Apr 15;120(8):1255-62. doi: 10.1002/cncr.28524. Epub 2014 Jan 10. Cancer. 2014. PMID: 24415457
-
Antibacterial prophylaxis in pediatric patients with leukemia.Saudi Pharm J. 2018 Sep;26(6):810-816. doi: 10.1016/j.jsps.2018.04.002. Epub 2018 Apr 3. Saudi Pharm J. 2018. PMID: 30202221 Free PMC article. Review.
-
Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.Pharmacoeconomics. 2001;19(11):1135-75. doi: 10.2165/00019053-200119110-00006. Pharmacoeconomics. 2001. PMID: 11735679 Review.
Cited by
-
Prevention and Management of Infectious Complications in Pediatric Patients With Cancer: A Survey Assessment of Current Practices Across Children's Oncology Group Institutions.Pediatr Blood Cancer. 2025 Mar;72(3):e31532. doi: 10.1002/pbc.31532. Epub 2025 Jan 8. Pediatr Blood Cancer. 2025. PMID: 39780366
-
Infections with Staphylococcus spp. in Children Undergoing Anticancer Therapy or Haematopoietic Cell Transplantation: A Nationwide Multicentre Study.J Clin Med. 2025 Jul 22;14(15):5200. doi: 10.3390/jcm14155200. J Clin Med. 2025. PMID: 40806822 Free PMC article.
References
-
- Reedijk A.M.J., Klein K., Coebergh J.W.W., Kremer L.C., Dinmohamed A.G., de Haas V., Versluijs A.B., Ossenkoppele G.J., Beverloo H.B., Pieters R., et al. Improved survival for children and young adolescents with acute myeloid leukemia: A Dutch study on incidence, survival and mortality. Leukemia. 2019;33:1349–1359. doi: 10.1038/s41375-018-0314-7. - DOI - PubMed
-
- De Moerloose B., Reedijk A., de Bock G.H., Lammens T., de Haas V., Denys B., Dedeken L., Heuvel-Eibrink M.M.V.D., Loo M.T., Uyttebroeck A., et al. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01. Pediatr. Blood Cancer. 2019;66:e27605. doi: 10.1002/pbc.27605. - DOI - PubMed
-
- Rasche M., Zimmermann M., Borschel L., Bourquin J.P., Dworzak M., Klingebiel T., Lehrnbecher T., Creutzig U., Klusmann J.-H., Reinhardt D. Successes and challenges in the treatment of pediatric acute myeloid leukemia: A retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018;32:2167–2177. doi: 10.1038/s41375-018-0071-7. - DOI - PMC - PubMed
-
- Creutzig U., Zimmermann M., Reinhardt D., Dworzak M., Stary J., Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J. Clin. Oncol. 2004;22:4384–4393. doi: 10.1200/JCO.2004.01.191. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous